Effects of Ambroxol combined with Meropenem in treatment of patients with chronic obstructive pulmonary disease complicated with pulmonary infection
Objective:To observe effects of Ambroxol combined with Meropenem in treatment of patients with chronic obstructive pulmonary disease(COPD)complicated with pulmonary infection.Methods:The clinical data of 65 patients with COPD complicated with pulmonary infection admitted to this hospital from November 2021 to February 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group(n=32)and observation group(n=33).The control group was treated with Meropenem,while the observation group was treated with Ambroxol on the basis of that of the control group.The clinical efficacy,the disappearance time of clinical signs,the lung function indexes[forced vital capacity(FVC),forced expiratory volume in one second(FEV1),maximum mid-expiratory flow(MMEF),the 6 min walking distance(6MWD)],the blood gas indexes[arterial partial pressure of carbon dioxide(PaCO2),arterial partial pressure of oxygen(PaO2)]levels,the inflammatory factors[cystatin C(Cys-C),procalcitonin(PCT),C-reactive protein(CRP),interleukin-6(IL-6)]levels,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of the observation group was 96.97% (32/33),which was higher than the control group of 75.00% (24/32),and the difference was statistically significant(P<0.05).After the treatment,the disappearance time of cough,moist rales and dyspnea in the observation group was shorter than that in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of FVC,MMEF,FEV1 and 6MWD in the two groups were higher than those before the treatment,those in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the PaO2 levels of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the PaCO2 levels of the two groups were lower than those before the treatment,and that in the observation group was lower than that in the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of Cys-C,IL-6,PCT and CRP in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Ambroxol combined with Meropenem in the treatment of the COPD patients with pulmonary infection can improve the clinical efficacy,promote the disappearance of clinical symptoms,improve the lung function and the blood gas index levels,and reduce the body's inflammatory response.Moreover,it is superior to single Meropenem treatment.
万方数据
维普
